Tumeur desmoïde. À propos de quatre cas

Résidence Ibnou-Khaldoun, B 40, rue Oued-El-Makhazine, Harhoura-Temara, Maroc
Journal Africain d?Hépato-Gastroentérologie 09/2010; 4(3):156-160. DOI: 10.1007/s12157-010-0174-x

ABSTRACT IntroductionLa tumeur desmoïde est une affection rare se développant aux dépens des muscles et de leurs aponévroses se caractérisant par
une malignité locale et une forte tendance aux récidives.

Matériel et méthodesNous rapportons quatre cas colligés dans le service de chirurgie générale de l’hôpital militaire Avicenne de Marrakech au
Maroc sur une période de dix ans de 1998 à 2008 inclus.

RésultatNotre étude concerne trois femmes et un homme. Le siège de la tumeur était aux dépens du muscle grand droit dans trois cas,
soléaire dans un cas. L’imagerie médicale a confirmé le diagnostic, et le traitement était chirurgical dans tous les cas.
Aucun cas de récidive n’a été signalé.

DiscussionLes tumeurs desmoïdes sont des tumeurs bénignes rares caractérisées par une malignité locale avec une grande tendance à la
récidive. Elles surviennent chez l’adulte jeune surtout la femme en âge de procréer. Nous rapportons quatre cas de tumeur
desmoïde extra-abdominale. Le traitement était essentiellement chirurgical sans aucun signe de récidive.

ConclusionLes tumeurs desmoïdes sont rares formant une entité clinique particulière par leur évolution lente et les possibilités thérapeutiques
diverses. Le pronostic est généralement bon après une exérèse chirurgicale complète.

IntroductionThe desmoid tumor is a rare disease which develops at the expense of the muscles and their aponeurosis, being characterized
by a local malignancy and a strong tendency to relapse.

Material and methodsWe report four cases diagnosed in the service of general surgery over a period of ten years (1998 to 2008 included).

ResultOur survey concerns 3 women and a man. The site of the tumor was at the right big muscle in three cases and at the calf in
one case. The medical imaging confirmed the diagnosis, and the treatment was surgical in all cases. No case of recidivism
has been reported.

DiscussionThe desmoid tumor is a rare benign tumor characterized by a local malignancy with a strong tendency to relapse. They especially
occur in young adult women of childbearing age. We report four cases of extra-abdominal desmoid tumor. The treatment was essentially
surgical without any sign of recidivism.

ConclusionThe desmoid tumor is rare forming a particular clinical entity by their slow evolution and the various therapeutic possibilities.
The prognosis is generally good after complete surgical excision.

Mots clésTumeurs desmoïdes-Fibromatoses agressives-Fibrosarcomes-Syndrome de Gardner-Traitement chirurgical-Chimiothérapie et radiothérapie
KeywordsDesmoid tumours-Aggressive fibromatosis-Fibrosarcomas-Gardner syndrome-Surgical treatment-Chemotherapy and radiotherapy

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods. Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994. A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20% was improved compared with the 30% rate observed in the earlier series. Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.
    Journal of Clinical Oncology 06/2007; 25(13):1785-91. DOI:10.1200/JCO.2006.10.5015 · 17.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Desmoid tumors are a rare form of malignancy with a great propensity for local extension and recurrence. They typically occur in the abdominal wall or within the abdomen but also may occur extra-abdominally. Most cases are sporadic but traumatic, hormonal, and genetic etiologies have been implicated. The only curative treatment is wide surgical excision, but the risk of local recurrence is high. Several adjuvant or complementary treatments have been proposed and the results show promise; the authors review all these therapies.
    Journal de Chirurgie 02/2008; 145(1):20-26. DOI:10.1016/S0021-7697(08)70288-6 · 0.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extra-abdominal desmoid tumors are rare neoplasms with variable biological behavior. The mainstay of treatment is surgery. Complementary treatment with tyrosine-kinase receptor inhibitor drugs, particularly imatinib mesylate, has been reported in the literature. The purpose of this study was to determine the possible presence of tyrosine-kinase receptors in extra-abdominal desmoid tumors as a marker for imatinib mesylate therapy. From 1999 to 2004, immunohistochemical methods were carried-out in 14 patients with histologically confirmed extra-abdominal desmoid tumors to determine c-KIT positivity (existence of tyrosine-kinase receptors and PDGFRA and PDGFRB). All desmoid tumors were c-KIT negative, which demonstrates absence of tyrosine-kinase receptors. The histological c-KIT markup is an easy and reliable method that can detect whether a desmoid tumor is sensitive to additional treatment with a tyrosine-kinase receptor inhibitor. Molecular biological analysis for the identification of KIT and PDGFR mutation should be performed before imatinib mesylate is included in any treatment protocol.
    Anticancer research 01/2007; 27(2):1143-7. · 1.87 Impact Factor